AstraZeneca PLC (AZN) Price and Market Data

AstraZeneca PLC was created in 1999 through the merger of Sweden’s Astra and the United Kingdom’s Zeneca. The company markets branded pharmaceuticals across several major therapeutic areas, led by oncology, which generates more than 40% of total revenue. Its portfolio also includes cardiovascular, renal, and metabolic therapies (over 20%), rare disease treatments (16%), and respiratory and immunology products (15%). AstraZeneca derives most of its revenue from international markets, while the United States accounts for nearly one-third of total sales.